Genetic Signatures Future Growth
Future criteria checks 6/6
Genetic Signatures is forecast to grow earnings and revenue by 98.6% and 41.9% per annum respectively. EPS is expected to grow by 101.1% per annum. Return on equity is forecast to be 24.7% in 3 years.
Key information
98.6%
Earnings growth rate
101.1%
EPS growth rate
| Life Sciences earnings growth | 20.4% |
| Revenue growth rate | 41.9% |
| Future return on equity | 24.7% |
| Analyst coverage | Low |
| Last updated | 31 Oct 2024 |
Recent future growth updates
Recent updates
Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult
Jun 14
After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar
Mar 08A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)
Nov 14Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected
Oct 10One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates
Jun 29Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Feb 28AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results
Feb 25What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?
Feb 07
What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?
Jan 17Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth
Dec 27Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business
Dec 06Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2027 | 72 | 20 | 13 | 19 | 1 |
| 6/30/2026 | 46 | 3 | -5 | 1 | 1 |
| 6/30/2025 | 24 | -11 | -15 | -10 | 1 |
| 6/30/2024 | 14 | -18 | -15 | -10 | N/A |
| 3/31/2024 | 15 | -18 | -16 | -10 | N/A |
| 12/31/2023 | 16 | -18 | -16 | -10 | N/A |
| 9/30/2023 | 19 | -16 | -18 | -11 | N/A |
| 6/30/2023 | 22 | -14 | -21 | -12 | N/A |
| 3/31/2023 | 23 | -11 | -16 | -8 | N/A |
| 12/31/2022 | 24 | -8 | -11 | -3 | N/A |
| 9/30/2022 | 30 | -3 | -2 | 3 | N/A |
| 6/30/2022 | 35 | 3 | 7 | 10 | N/A |
| 3/31/2022 | 33 | 3 | 4 | 7 | N/A |
| 12/31/2021 | 31 | 2 | 1 | 4 | N/A |
| 9/30/2021 | 30 | 2 | 0 | 4 | N/A |
| 6/30/2021 | 28 | 2 | -1 | 4 | N/A |
| 3/31/2021 | 29 | 3 | -3 | 2 | N/A |
| 12/31/2020 | 29 | 5 | -5 | -1 | N/A |
| 9/30/2020 | 21 | 1 | -9 | -5 | N/A |
| 6/30/2020 | 14 | -2 | -12 | -9 | N/A |
| 3/31/2020 | 11 | -3 | -8 | -6 | N/A |
| 12/31/2019 | 7 | -4 | -4 | -3 | N/A |
| 9/30/2019 | 7 | -4 | -3 | -3 | N/A |
| 6/30/2019 | 7 | -3 | -3 | -2 | N/A |
| 3/31/2019 | 7 | -3 | -3 | -2 | N/A |
| 12/31/2018 | 6 | -3 | -3 | -2 | N/A |
| 9/30/2018 | 5 | -3 | -4 | -3 | N/A |
| 6/30/2018 | 5 | -3 | -4 | -4 | N/A |
| 3/31/2018 | 5 | -3 | N/A | -3 | N/A |
| 12/31/2017 | 5 | -3 | N/A | -3 | N/A |
| 9/30/2017 | 4 | -3 | N/A | -3 | N/A |
| 6/30/2017 | 4 | -3 | N/A | -3 | N/A |
| 3/31/2017 | 4 | -3 | N/A | -2 | N/A |
| 12/31/2016 | 4 | -3 | N/A | -2 | N/A |
| 9/30/2016 | 3 | -3 | N/A | -2 | N/A |
| 6/30/2016 | 3 | -3 | N/A | -3 | N/A |
| 3/31/2016 | 3 | -3 | N/A | -3 | N/A |
| 12/31/2015 | 3 | -3 | N/A | -3 | N/A |
| 9/30/2015 | 2 | -3 | N/A | -3 | N/A |
| 6/30/2015 | 2 | -3 | N/A | -3 | N/A |
| 6/30/2014 | 1 | -2 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GSS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: GSS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: GSS is expected to become profitable in the next 3 years.
Revenue vs Market: GSS's revenue (41.9% per year) is forecast to grow faster than the Australian market (5.8% per year).
High Growth Revenue: GSS's revenue (41.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GSS's Return on Equity is forecast to be high in 3 years time (24.7%)
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 02:19 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genetic Signatures Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anubhav Saxena | Bell Potter |
| Thomas Wakim | Bell Potter |